Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 22, 2021

Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates the potential for treating a variety of solid cancers and COVID-19’s post-recovery complications, which include heart damage, diabetes, and multi-system inflammatory syndrome in children (MIS-C).

This research was recently submitted as a preprint publication on bioRxiv.org.

Aggressive solid cancers have been known to manipulate immunity for their advancements in several ways. One way is the enrichment of an immunity subset called M2-like macrophages (M2), which is associated with cancer metastasis, relapse, and treatment resistance. Recent studies showed that COVID-19 infection resulted in similar immune pathologies to solid cancers – increased M2 activity and suppressed CD4 and CD8 T-cells[1] activity.

Xylonix demonstrated that its drug compound 010DS-Zn markedly reduced M2 population, while simultaneously boosting anti-cancer CD4 and CD8 T cells. This resulted in tumor suppression in animal studies. It also demonstrated consistent anti-cancer activity in 53 human patient-derived cancers tested ex vivo.

“Today’s cancer immunotherapy combinations can cost upwards of $200,000/year (1), but beneficial responses in patients happen at 15% chance-at-random (2). We developed 010DS-Zn as a widely applicable immunotherapy to significantly increase these odds. As of today, we are concerned about the 120 million and more people (3) with COVID-19 infection history who may suffer from long-term recovery complications. We have manufactured a sufficient quantity of 010DS-Zn to be used for multiple collaborations, and we are looking for capable partners to work with us on further studies on 010DS-Zn’s effect on human tumors and COVID-19 complications,” said Dr Fred Chung, Chief Scientific Officer and Co-founder Xylonix.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine